+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Benign Prostatic Hyperplasia (BPH) Drugs - Global Market Trajectory & Analytics

  • ID: 5309387
  • Report
  • April 2021
  • Region: Global
  • 134 pages
  • Global Industry Analysts, Inc
1 of 2
Global Benign Prostatic Hyperplasia (BPH) Drugs Market to Reach $6.6 Billion by 2027

Amid the COVID-19 crisis, the global market for Benign Prostatic Hyperplasia (BPH) Drugs estimated at US$4.5 Billion in the year 2020, is projected to reach a revised size of US$6.6 Billion by 2027, growing at a CAGR of 5.6% over the analysis period 2020-2027. Alpha-Blockers, one of the segments analyzed in the report, is projected to record a 5.9% CAGR and reach US$4.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the 5-ARIs segment is readjusted to a revised 5.1% CAGR for the next 7-year period.



The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 5.2% CAGR

The Benign Prostatic Hyperplasia (BPH) Drugs market in the U.S. is estimated at US$1.3 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2027 trailing a CAGR of 5.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 4.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

PDE-5 Inhibitors Segment to Record 5.7% CAGR

In the global PDE-5 Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 5.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$347.5 Million in the year 2020 will reach a projected size of US$514.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$762.9 Million by the year 2027.

Select Competitors (Total 44 Featured):
  • ADC Therapeutics SA
  • Advaxis, Inc.
  • Agennix AG
  • ANI Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.
  • Bayer Healthcare AG
  • BHR Pharma, LLC.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • Ferring Pharmaceuticals, Inc.
  • Foresee Pharmaceuticals Co., Ltd.
  • GlaxoSmithKline PLC
  • Io Therapeutics Inc.
  • LIDDS AB (publ)
  • Madrigal Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Nymox Pharmaceutical Corporation
  • Sanofi
  • Spectrum Pharmaceuticals
  • Takeda Pharmaceuticals Company Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Urologix, Inc.
Note: Product cover images may vary from those shown
2 of 2
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Alpha-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Alpha-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Alpha-Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for 5-ARIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for 5-ARIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for 5-ARIs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for PDE-5 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for PDE-5 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for PDE-5 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • Table 16: USA Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 17: USA Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 18: USA 15-Year Perspective for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • Table 19: Canada Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 20: Canada Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 21: Canada 15-Year Perspective for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • Table 22: Japan Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 23: Japan Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 24: Japan 15-Year Perspective for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • Table 25: China Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: China Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 27: China 15-Year Perspective for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • Table 28: Europe Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 29: Europe Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 30: Europe 15-Year Perspective for Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 31: Europe Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: Europe Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 33: Europe 15-Year Perspective for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • Table 34: France Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 35: France Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 36: France 15-Year Perspective for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • Table 37: Germany Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: Germany Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 39: Germany 15-Year Perspective for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • Table 40: Italy Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 41: Italy Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 42: Italy 15-Year Perspective for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • Table 43: UK Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: UK Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 45: UK 15-Year Perspective for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • Table 46: Rest of Europe Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 47: Rest of Europe Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 48: Rest of Europe 15-Year Perspective for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • Table 49: Asia-Pacific Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: Asia-Pacific Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 51: Asia-Pacific 15-Year Perspective for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • Table 52: Rest of World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 53: Rest of World Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 54: Rest of World 15-Year Perspective for Benign Prostatic Hyperplasia (BPH) Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Alpha-Blockers, 5-ARIs, PDE-5 Inhibitors and Other Therapeutic Classes for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 44
Note: Product cover images may vary from those shown
Adroll
adroll